KEY POINTS
- This collaborative technical paper from three established proton therapy institutions describes planning and delivery for three challenging liver tumors: a large hepatocellular carcinoma treated in 15 fractions, a similarly large HCC treated with five-fraction proton SBRT, and a liver oligometastasis treated with spatially fractionated proton therapy followed by conventionally fractionated IMPT.
- Case 1 involved a roughly 10–12 cm HCC with gross tumor volume approximately 1,203 cc, treated using deep-inspiration breath hold. Prescription was 45 Gy(RBE) in 15 fractions, with a simultaneous integrated boost of 67.5 Gy(RBE) to a contracted central target; planning used two fields, repainting, and robustness evaluation with 5 mm setup and 3.5% range uncertainty.
- In Case 1, more than 99.5% of the relevant target volume received at least 95% of prescription under all evaluated robustness scenarios. Daily kV imaging and CBCT assessed soft-tissue alignment, diaphragm position and proton beam-path changes; the patient experienced no grade ≥2 toxicity and remained without recurrence approximately two years after treatment.
- Case 2 involved a 9.6 cm HCC treated to 50 Gy(RBE) in five fractions. Because breath hold was not tolerated, abdominal compression was used, leaving mean superior-inferior displacement of 5.2 mm; four proton fields were selected to mitigate motion interplay and range uncertainty, with a mean uninvolved-liver dose of 11.04 Gy(RBE).
- Case 2 achieved CTV V99% of 95% in the nominal plan, while patient-specific QA exceeded 99% gamma passing rate at 3%/3 mm. No grade ≥2 acute or late toxicity occurred through one-year follow-up, although these results represent one carefully selected patient rather than evidence for the safety of five-fraction treatment in all large HCC lesions.
- Case 3 involved a 4.7 cm liver oligometastasis adjacent to the stomach and bowel. A proton GRID fraction delivered approximately 15 Gy(RBE) to 3-mm cylindrical targets spaced 2.3 cm apart, followed by IMPT delivering 58.05 Gy(RBE) in 15 fractions to the boost target and 45 Gy(RBE) to the larger target; GRID delivery required 48 seconds, with a peak-to-valley dose ratio of approximately 3.5–4.
- Across the cases, the authors emphasize site-specific motion management, beam-angle selection, robust optimization, verification of bowel and diaphragm position, and repeat imaging when anatomical changes threaten dose distribution. The third patient remained locally controlled at 18 months but developed distant progression at 14 months, and the overall three-case report cannot establish comparative tumor control or toxicity advantages.
CLINICAL TAKEAWAY
The paper provides practical examples of adapting liver IMPT planning to tumor size, respiratory motion, gastrointestinal proximity and available treatment technology. Its value lies in reproducible technical strategies rather than efficacy evidence; the proposed approaches require local commissioning, patient-specific robustness assessment and experienced multidisciplinary judgment.